These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34499320)

  • 21. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
    Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
    Front Immunol; 2020; 11():546. PubMed ID: 32300346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
    Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
    Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
    Martinez DR; Metz SW; Baric RS
    Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
    Rajpoot RK; Shukla R; Arora U; Swaminathan S; Khanna N
    Sci Rep; 2018 Jun; 8(1):8643. PubMed ID: 29872153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying protective dengue vaccines: guide to mastering an empirical process.
    Halstead SB
    Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How innate immune mechanisms contribute to antibody-enhanced viral infections.
    Ubol S; Halstead SB
    Clin Vaccine Immunol; 2010 Dec; 17(12):1829-35. PubMed ID: 20876821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.